BIRC6 Antibody

BIRC6 is a member of a family of proteins that inhibit apoptosis, likely through interference with activation of ICE-like proteases. BIRC6 which contains a single BIR domain and a ubiquitin-conjugating enzyme domain, is expressed in multiple cancer cell lines. Brain cancer cell lines that overexpress BIRC6 demonstrate multi-drug resistanceimplying that BIRC6 may protect cancer cells from undergoing apoptosis and participate in tumorigenesis and drug resistance.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: IF/IHC, IHC-P, WB.

Showing Publications 1 - 5 of 5.

Publications using NB110-40730	Applications	Species
Zhuang W, Zhang C, Hao F, Sun X. Baculoviral IAP Repeat Containing 6 (BIRC6) Is a Predictor of Prognosis in Prostate Cancer. Med. Sci. Monit. 2018-02-10 [PMID: 29429983] (IHC-P, Human)	IHC-P	Human
Luk IS, Shrestha R, Xue H et al. BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer Clin. Cancer Res. 2016-09-23 [PMID: 27663589] (IF/IHC, WB, Human)	IF/IHC, WB	Human
Luk Sze Ue Iris, Xue Hui, Cheng Hongwei et al. The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget. 2014-08-30 [PMID: 25071009] (WB)	WB
Low CG, Luk IS, Lin D et al. BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. PLoS One 2013-01-01 [PMID: 23409057] (WB, IF/IHC, Human)	WB, IF/IHC	Human
Dong X, Lin D, Low C et al. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. J Thorac Oncol 2013-02-01 [PMID: 23287853]

Array NB110-40730

• BIRC6 Antibodies
• BIRC6 ELISA Kits
• BIRC6 Proteins